Skip to content
Home/Companies/Pharma/Akinion Pharmaceuticals

Akinion Pharmaceuticals

Pharma·Sweden·Active·13yr hold
Entry
2013
Hold
13yr
Status
Active

Who owns Akinion Pharmaceuticals?

Akinion Pharmaceuticals is currently owned by Rosetta Capital through Rosetta Capital IV (2013 vintage), since 2013.

Hand-verified · updated 2026-06-30

Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorPharma
StatusActive

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Aprea Therapeutics
Exited 2019
BiotechSweden· 2013
Axelar
Active
BiotechSweden· 2013
Biosergen
Exited 2021
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Dilafor
Active
BiotechSweden· 2013
Inhalation Sciences
Inhalation Sciences
Active
MedTechSweden· 2013

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track Akinion Pharmaceuticals

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Akinion Pharmaceuticals?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Akinion Pharmaceuticals.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue